CB-839 is primarily utilized in the field of cancer research and treatment. It functions as a glutaminase inhibitor, targeting and blocking the activity of the enzyme glutaminase, which is crucial for cancer cell metabolism. By inhibiting this enzyme, CB-839 disrupts the ability of cancer cells to utilize glutamine, an essential nutrient for their growth and survival. This makes it particularly effective in targeting cancers that are highly dependent on glutamine, such as certain types of triple-negative breast cancer, lung cancer, and renal cell carcinoma. CB-839 is often investigated in combination with other therapies, including chemotherapy and immunotherapy, to enhance its efficacy and improve patient outcomes. Its role in clinical trials continues to expand as researchers explore its potential in treating various malignancies and overcoming drug resistance in cancer cells.